Nanospectra Biosciences, Inc.

17 articles about Nanospectra Biosciences, Inc.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• Nanospectra Biosciences Announces Enrollment Completion of Pivotal Study of AuroLase Therapy for Ablation of Prostate TissueEnd of Study Top-line Data Available Late-2022

  11/2/2021

  Nanospectra Biosciences, Inc. today announced the completion of enrollment of its open-label, multi-center, single-treatment pivotal study of AuroLase Therapy for focal ablation of prostate tissue via nanoparticle directed near infrared irradiation.

• Sirtex Medical announces strategic investment in Nanospectra Biosciences

  9/8/2020

  Agreement includes board position and exclusive negotiation period for further collaborative access to AuroLase® Therapy in other non-U.S. geographies.

• Nanospectra Biosciences Raises First Tranche of Series B-1 Funding Led by Sirtex Medical

  9/8/2020

   Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 mi

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

• Nanospectra Biosciences Announces Four Additional Prestigious Trial Sites for Pivotal AuroLase Study

  8/4/2020

  Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase® pivotal study. T

• Nanospectra Biosciences Initiates Pivotal Study of AuroLase Therapy for Ablation of Prostate Tissue

  2/4/2020

  Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the start of a pivotal study to determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser ablation.

• 

  Clinical Catch-Up: August 25-30

  9/3/2019

  Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

• Nanospectra Biosciences Announces PNAS Publication of Initial Results of First Clinical Trial of Gold Nanoshell-Localized Photothermal Ablation of Prostate Tissue

  8/27/2019

  Nanospectra Biosciences, Inc. announced publication of first in human data of the company's AuroLase® Therapy for the focal ablation of prostate tissue.

• Nanospectra Biosciences Announces University of Texas Medical Branch at Galveston as Clinical Trial Site

  3/27/2019

  Nanospectra Biosciences, Inc. announced the addition of University of Texas Medical Branch at Galveston as the fifth trial site in its pilot feasibility study "MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue".

• Nanospectra Biosciences Recognized as a ‘Houston Innovation Success’ at Congressional Healthcare Innovations Summit

  2/21/2019

  Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company was the featured innovation success at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University

• 

  BioSpace Movers and Shakers: Feb. 1

  2/1/2019

  As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.

• Nanospectra Biosciences Names Michael Brawer, M.D. as Chief Medical Officer

  1/29/2019

  Nanospectra Biosciences, Inc. today announced the appointment of Michael Brawer, M.D., as Chief Medical Officer (CMO). Dr. Brawer will assume responsibility for leading Nanospectra's overall clinical development, regulatory, and medical affairs activities, effective immediately.

• Nanospectra Biosciences Technology Advances Partner Products to US Commercialization

  10/30/2018

  Nanospectra Biosciences, Inc. today announced that two of its commercial partners, Sebacia, Inc. and LiteCure, LLC, have advanced towards commercialization and indicated plans for commercial launch in the United States in 2019.

• Nanospectra Biosciences Provides Corporate Update

  3/28/2018

  Company Completes Critical Steps Towards Commercialization of AuroLase Therapy for Solid Tumor Ablation for Localized Prostate Cancer

• Nanospectra Biosciences, Inc. Raises $1 Million As It Moves Through Clinical Trials

  12/22/2015

• Gold Nanoshells Help Visibly Heat And Destroy Cancer, University of Texas M. D. Anderson Cancer Center and Nanospectra Biosciences, Inc. Study

  8/6/2008